Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy

The aim of the study was to analyze granted drug provision for asthma (BA) patients at Samara region to spend healthcare resources more rationally and to improve asthma patients' quality of life. This population-based study of drug therapy involved 19,697 BA patients surveyed at Samara region in 2003–2004. The analysis was performed using a personified database of the granted drug provision and integral parameters of health. We used multi-factorial statistical analysis with mathematical modelling. The results demonstrated that the healthcare quality for BA patients depends on a structure of the drug therapy. A model of basic anti-asthmatic therapy for Samara region was created using the study results.

Download Full-text

Factors associated with adherence to drug therapy: a population-based study

European Journal of Clinical Pharmacology ◽

10.1007/s00228-006-0246-4 ◽

2007 ◽

Vol 63 (3) ◽

pp. 307-314 ◽

Cited By ~ 32

Author(s):

Annika Bardel ◽

Mari-Ann Wallander ◽

Kurt Svärdsudd

Keyword(s):

Drug Therapy ◽

Population Based ◽

Population Based Study ◽

Factors Associated

Download Full-text

Estimation of total cardiovascular risk using the 2019 WHO CVD prediction charts and comparison of population-level costs based on alternative drug therapy guidelines: a population-based study of adults in Bangladesh

BMJ Open ◽

10.1136/bmjopen-2019-035842 ◽

2020 ◽

Vol 10 (7) ◽

pp. e035842

Author(s):

Jessica Yasmine Islam ◽

M Mostafa Zaman ◽

Mohammad Moniruzzaman ◽

Shawkat Ara Shakoor ◽

A H M Enayet Hossain

Keyword(s):

Drug Therapy ◽

Risk Prediction ◽

Primary Outcome ◽

Population Based ◽

Cvd Risk ◽

Cross Sectional ◽

Population Based Study ◽

Single Risk Factor ◽

Risk Approach ◽

Very High

ObjectiveThe objective of this study was to estimate the population distribution of 10-year cardiovascular disease (CVD) risk among Bangladeshi adults aged 40 years and above, using the 2019 WHO CVD risk prediction charts. Additionally, we compared the cost of CVD pharmacological treatment based on the total CVD risk (thresholds ≥30%/≥20%) and the single risk factor (hypertension) cut-off levels in the Bangladeshi context.Study designCross-sectional, population-based study.Setting and participantsFrom 2013 to 2014, we collected data from a nationally representative cross-sectional survey of adults aged ≥40 years from urban and rural areas of Bangladesh (n=6189). We estimated CVD risk using the 2019 WHO CVD risk prediction charts and categorised as very low (<5%), low (5% to <10%), moderate (10% to <20%), high (20% to <30%) and very high risk (≥30%). We estimated drug therapy costs using the lowest price of each drug class available (aspirin, thiazide diuretics, statins and ACE inhibitors). We compared the total cost of drug therapy using the total CVD risk versus single risk factor approach.Primary outcome measuresOur primary outcome was 10-year CVD risk categorised as very low (<5%), low (5% to <10%), moderate (10% to <20%), high (20% to <30%) and very high risk (≥30%).ResultsThe majority of adults (85.2%, 95% CI 84.3 to 86.1) have a 10-year CVD risk of less than 10%. The proportion of adults with a 10-year CVD risk of ≥20% was 0.51%. Only one adult was categorised with a 10-year CVD risk of ≥30%. Among adults with CVD risk groups of very low, low and moderate, 17.4%, 27.9% and 41.4% had hypertension (blood pressure (BP) ≥140/90) and 0.1%, 1.7% and 2.9% had severe hypertension (BP ≥160/100), respectively. Using the total CVD risk approach would reduce drug costs per million populations to US$144 540 (risk of ≥20%).ConclusionTo reduce healthcare expenditure for the prevention and treatment of CVD, a total risk approach using the 2019 WHO CVD risk prediction charts may lead to cost savings.

Download Full-text